The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Hernandez, Yasmin ^a   Sotolongo, John ^c   Breglio, Keith ^a   Conduah, Daisy ^a   Chen, Anli ^a   Xu, Ruliang ^b   Hsu, David ^a   Ungaro, Ryan ^a   Hayes, Lory A ^c   Pastorini, Cristhine ^c   Abreu, Maria T ^c   Fukata, Masayuki ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; AZOXYMETHANE; CYCLOOXYGENASE 2; DEXTRAN SULFATE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROSTAGLANDIN E2; PROSTANOID; TOLL LIKE RECEPTOR 4; GLYCOPROTEIN; PROSTAGLANDIN; SIGNAL PEPTIDE; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLITIS; COLITIS ASSOCIATED NEOPLASIA; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DYSPLASIA; GENE OVEREXPRESSION; LOW DRUG DOSE; MOUSE; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; COLON TUMOR; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENETICS; INTESTINE MUCOSA; MALE; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; AZOXYMETHANE; CELL PROLIFERATION; COLITIS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; DEXTRAN SULFATE; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCOPROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROSTAGLANDINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 77954559878     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-82     Document Type: Article

References (64)

1. Fujiwara I, Yashiro M, Kubo N, Maeda K, Hirakawa K. Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. Diseases of the Colon & Rectum 2008, 51(9):1387-1394.
2. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48(4):526-535. 10.1136/gut.48.4.526, 1728259, 11247898.
3. Chen R, Rabinovitch PS, Crispin DA, Emond MJ, Bronner MP, Brentnall TA. The initiation of colon cancer in a chronic inflammatory setting. Carcinogenesis 2005, 26(9):1513-1519. 10.1093/carcin/bgi106, 15860506.
4. Morita H, Nakanishi K, Dohi T, Yasugi E, Oshima M. Phospholipid turnover in the inflamed intestinal mucosa: Arachidonic acid-rich phosphatidyl/plasmenyl-ethanolamine in the mucosa in inflammatory bowel disease. Journal of Gastroenterology 1999, 34(1):46-53. 10.1007/s005350050215, 10204610.
5. Stanke-Labesque F, Pofelski J, Moreau-Gaudry A, Bessard G, Bonaz B. Urinary leukotriene E-4 excretion: A biomarker of inflammatory bowel disease activity. Inflamm Bowel Dis 2008, 14(6):769-774. 10.1002/ibd.20403, 18286646.
6. Wallace JL. Prostaglandin biology in inflammatory bowel disease. Gastroenterology Clinics of North America 2001, 30(4):971. 10.1016/S0889-8553(05)70223-5, 11764538.
7. Shiraishi H, Yoshida H, Saeki K, Miura Y, Watanabe S, Ishizaki T, Hashimoto M, Takaesu G, Kobayashi T, Yoshimura A. Prostaglandin E-2 is a major soluble factor produced by stromal cells for preventing inflammatory cytokine production from dendritic cells. International Immunology 2008, 20(9):1219-1229. 10.1093/intimm/dxn078, 18640970.
8. Okano M, Sugata Y, Fujiwara T, Matsumoto R, Nishibori M, Shimizu K, Maeda M, Kimura Y, Kariya S, Hattori H, Yokoyama M, Kino K, Nishizaki K. E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E-2. Immunology 2006, 118(3):343-352. 10.1111/j.1365-2567.2006.02376.x, 1782299, 16827895.
9. Blikslager AT, Roberts MC, Rhoads JM, Argenzio RA. Prostaglandins I-2 and E-2 have a synergistic role in rescuing epithelial barrier function in porcine ileum. Journal of Clinical Investigation 1997, 100(8):1928-1933. 10.1172/JCI119723, 508381, 9329955.
10. Banan A, Smith GS, Deshpande Y, Rieckenberg CL, Kokoska ER, Miller TA. Prostaglandins protect human intestinal cells against ethanol injury by stabilizing microtubules - Role of protein kinase C and enhanced calcium efflux. Digestive Diseases and Sciences 1999, 44(4):697-707. 10.1023/A:1026649422607, 10219825.
11. Brzozowski T, Konturek PC, Konturek SJ, Brzozowska I, Pawlik T. Role of prostaglandins in gastroprotection and gastric adaptation. J Physiol Pharmacol 2005, 56(Suppl 5):33-55.
12. Muller-Decker K, Furstenberger G. The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog 2007, 46(8):705-710. 10.1002/mc.20326, 17546626.
13. Mauritz I, Westermayer S, Marian B, Erlach N, Grusch M, Holzmann K. Prostaglandin E-2 stimulates progression-related gene expression in early colorectal adenoma cells. British Journal of Cancer 2006, 94(11):1718-1725. 2361321, 16685273.
14. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993, 80(12):1618-1619. 10.1002/bjs.1800801244, 8298943.
15. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993, 328(18):1313-1316. 10.1056/NEJM199305063281805, 8385741.
16. Wang DZ, Wang HB, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK, DuBois RN. Prostaglandin E-2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 2004, 6(3):285-295. 10.1016/j.ccr.2004.08.011, 15380519.
17. O'Callaghan G, Kelly J, Shanahan F, Houston A. Prostaglandin E-2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells. British Journal of Cancer 2008, 99(3):502-512. 10.1038/sj.bjc.6604490, 2527805, 18648368.
18. Holla VR, Mann JR, Shi Q, DuBois RN. Prostaglandin E-2 regulates the nuclear receptor NR4A2 in colorectal cancer. Journal of Biological Chemistry 2006, 281(5):2676-2682. 10.1074/jbc.M507752200, 16293616.
19. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003, 278(37):35451-35457. 10.1074/jbc.M302474200, 12824187.
20. Tessner TG, Muhale F, Riehl TE, Anant S, Stenson WF. Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest 2004, 114(11):1676-1685. 529281, 15578100.
21. Malecka-Panas E, Kordek R, Biernat W, Tureaud J, Liberski PP, Majumdar AP. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Hepatogastroenterology 1997, 44(14):435-440.
22. Singer, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998, 115(2):297-306. 10.1016/S0016-5085(98)70196-9, 9679035.
23. Hendel J, Nielsen OH. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. American Journal of Gastroenterology 1997, 92(7):1170-1173.
24. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, Dubinett SM. Prostaglandin E-2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 2005, 65(14):6275-6281. 10.1158/0008-5472.CAN-05-0216, 16024629.
25. Mutoh M, Takahashi M, Wakabayashi K. Roles of prostanoids in colon carcinogenesis and their potential targeting for cancer chemoprevention. Current Pharmaceutical Design 2006, 12(19):2375-2382. 10.2174/138161206777698972, 16842185.
26. Wiercinska-Drapalo A, Flisiak R, Prokopowicz D. Mucosal and plasma prostaglandin E2 in ulcerative colitis. Hepato-Gastroenterology 1999, 46(28):2338-2342.
27. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, Xu R, Inoue H, Arditi M, Dannenberg AJ, Abreu MT. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology 2006, 131(3):862-877. 10.1053/j.gastro.2006.06.017, 2169292, 16952555.
28. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Abreu MT. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007, 133(6):1869-1881. 10.1053/j.gastro.2007.09.008, 2180834, 18054559.
29. Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 1996, 39(1):87-92. 10.1136/gut.39.1.87, 1383238, 8881816.
30. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993, 69(2):238-249.
31. Moolenbeek C, Ruitenberg EJ. The "Swiss roll": a simple technique for histological studies of the rodent intestine. Lab Anim 1981, 15(1):57-59. 10.1258/002367781780958577, 7022018.
32. Cooper HS, Murthy S, Kido K, Yoshitake H, Flanigan A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000, 21(4):757-768. 10.1093/carcin/21.4.757, 10753213.
33. Scher JU, Pillinger MH. 15d-PGJ2: the anti-inflammatory prostaglandin?. Clin Immunol 2005, 114(2):100-109. 10.1016/j.clim.2004.09.008, 15639643.
34. McShane LMKM, Wargovich MJ, Woods C, Purewal M, Freedman LS, Corle DK, Burt RW, Mateski DJ, Lawson M, Lanza E, O'Brien B, Lake W, Moler J, Schatzkin A. An evaluation of rectal mucosal proliferation measure variability sources in the polyp prevention trial: can we detect informative differences among individuals' proliferation measures amid the noise?. Cancer Epidemiol Biomarkers Prev 1998, 7(7):605-612.
35. Shao J, Lee SB, Guo H, Evers BM, Sheng H. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 2003, 63(17):5218-5223.
36. Coffey RJ, Hawkey CJ, Damstrup L, GravesDeal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL, Morrow JD. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(2):657-662. 10.1073/pnas.94.2.657, 19569, 9012840.
37. Al-Salihi MA, Ulmer SC, Doan T, Nelson CD, Crotty T, Prescott SM, Stafforini DM, Topham MK. Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and Tumor Necrosis Factor-alpha converting enzyme. Cellular Signalling 2007, 19(9):1956-1963. 10.1016/j.cellsig.2007.05.003, 2681182, 17572069.
38. Liu M, Yang SC, Sharma S, Luo J, Cui XY, Peebles KA, Huang M, Sato M, Ramirez RD, Shay JW, Minna JD, Dubinett SM. EGFR signaling is required for TGF-beta 1-Mediated COX-2 induction in human bronchial epithelial cells. American Journal of Respiratory Cell and Molecular Biology 2007, 37:578-588. 10.1165/rcmb.2007-0100OC, 2048680, 17600311.
39. Ahrenstedt O, Hallgren R, Knutson L. Jejunal release of prostaglandin-E(2) in Crohns-disease - Relation to disease-activity and first-degree relatives. Journal of Gastroenterology and Hepatology 1994, 9(6):539-543. 10.1111/j.1440-1746.1994.tb01557.x, 7865710.
40. Raab Y, Sundberg C, Hallgren R, Knutson L, Gerdin B. Mucosal synthesis and release of prostaglandin-E2 from activated eosinophils and macrophages in ulcerative-colitis. American Journal of Gastroenterology 1995, 90(4):614-620.
41. Lauritsen K, Hansen J, Bytzer P, Bukhave K, Raskmadsen J. Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium invivo dialysis of feces in patients with ulcerative-colitis and healthy controls. Gut 1984, 25(11):1271-1278. 10.1136/gut.25.11.1271, 1432314, 6149981.
42. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107(4):1183-1188.
43. Pugh S, Thomas GAO. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E(2). Gut 1994, 35(5):675-678. 10.1136/gut.35.5.675, 1374755, 8200564.
44. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon-cancer. Journal of Laboratory and Clinical Medicine 1993, 122(5):518-523.
45. Yang VW, Shields JM, Hamilton SR, Spannhake EW, Hubbard WC, Hylind LM, Robinson CR, Giardiello FM. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998, 58(8):1750-1753.
46. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E-2 protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 2002, 62(2):403-408.
47. Wilson JW, Potten CS. The effect of exogenous prostaglandin administration on tumor size and yield in Min/+ mice. Cancer Res 2000, 60(16):4645-4653.
48. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E-2 administration. Carcinogenesis 2003, 24(5):985-990. 10.1093/carcin/bgg033, 12771044.
49. Gurleyik G, Ozturk E, Adaleti R, Gunes P, Guran M, Peker O, Saglam A. Effects of prostaglandin E1 and E2 analogues on mucosal injury-induced, and on bacterial translocation promoted by, experimental intestinal obstruction. Journal of Investigative Surgery 2004, 17(3):127-134. 10.1080/08941930490446900, 15204956.
50. Okayama M, Hayashi S, Aoi Y, Nishio H, Kato S, Takeuchi K. Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS) - Induced colon lesions in rats. Digestive Diseases and Sciences 2007, 52(9):2095-2103. 10.1007/s10620-006-9597-z, 17429720.
51. Jiang GL, Nieves A, Im WB, Old DW, Dinh DT, Wheeler L. The prevention of colitis by E prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. Journal of Pharmacology and Experimental Therapeutics 2007, 320(1):22-28. 10.1124/jpet.106.111146, 17008451.
52. Hirata I, Murano M, Nitta M, Sasaki S, Toshina K, Maemura K, Katsu K. Estimation of mucosal inflammatory mediators in rat DSS-induced colitis - Possible role of PGE(2) in protection against mucosal damage. Digestion 2001, 63:73-80. 10.1159/000051915, 11173914.
53. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, Tsuboi K, Sugimoto Y, Kobayashi T, Miyachi Y, Ichikawa A, Narumiya S. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002, 109(7):883-893. 150928, 11927615.
54. Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T, Sugimoto Y, Negishi M, Narumiya S, Sugimura T, Wakabayashi K. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 2004, 53(8):1151-1158. 10.1136/gut.2003.028787, 1774140, 15247185.
55. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Narumiya S, Sugimura T, Wakabayashi K. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999, 59(20):5093-5096.
56. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Narumiya S, Sugimura T, Wakabayashi K. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002, 62(1):28-32.
57. Hull MAKS, Hawcroft G. Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer?. Mol Cancer Ther 2004, 3(8):1031-1039.
58. Fukata M, Michelsen KS, Eri R, Thomas LS, Hu B, Lukasek K, Nast CC, Lechago J, Xu R, Naiki Y, Soliman A, Arditi M, Abreu MT. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 2005, 288(5):G1055-1065. 10.1152/ajpgi.00328.2004, 15826931.
59. Brown SL, Riehl TE, Walker MR, Geske MJ, Doherty JM, Stenson WF, Stappenbeck TS. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J Clin Invest 2007, 117(1):258-269. 10.1172/JCI29159, 1716207, 17200722.
60. Pull SL, Doherty JM, Mills JC, Gordon JI, Stappenbeck TS. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci USA 2005, 102(1):99-104. 10.1073/pnas.0405979102, 544052, 15615857.
61. Hinz B, Brune K, Pahl A. Prostaglandin E(2) upregulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem Biophys Res Commun 2000, 272(3):744-748. 10.1006/bbrc.2000.2859, 10860826.
62. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355(9):885-895. 10.1056/NEJMoa061652, 16943401.
63. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355(9):873-884. 10.1056/NEJMoa061355, 16943400.
64. Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ. Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled, pilot study. Clinical Gastroenterology and Hepatology 2006, 4(2):203-211. 10.1016/j.cgh.2005.12.002, 16469681.